Perspectives
"Investment in biologics based medicine is gaining momentum as these drugs offer targeted therapy and often safer treatment options, higher returns on investment and slower erosion of market share post patent expiry compared to small molecule based drugs.
See our 20 pg report, "Ever Greening” To Remain Evergreen: Evolution of Antibody Technology to Drive M&A", for further details.
" ... Read more
6 Jan 2010 | From the latest Perspectives entry by Subita Srimal, Developing “Better Biologics” through "Evergreening "= High Value Proposition
Research Library . Recent Updates
| 4 Feb 2010 | Aurobindo - Market Perform - Good Business But Debt Raising Continues » |
|---|---|
| 4 Feb 2010 | WOCKHARDT, Positive Investment Alert - Emerging Visibility on Corporate Debt Restructuring » |
| 4 Feb 2010 | Chugai, Market Perform - 3Q Strong Tamiflu Sales Beats Projections, Improves Guidance » |
| 4 Feb 2010 | Takeda, Outperform - 3Q Results Review: In-line With Expected Results, Focus Remains on Pipeline » |
| 4 Feb 2010 | Astellas, Outperform - 3Q Results Review: Strong Sales of Global In-House and In-Licensed New Drugs » |
| 3 Feb 2010 | LLY, Outperform - Worst is priced in. Byetta LAR and Ph-II pipeline nws will act as stimulus in 1st » |
